Sosei Heptares cashes in on new Cambridge-California business enterprise
Cambridge-based Sosei Heptares and Aditum Bio in California have created a new company – Tempero Bio – to advance the clinical development of the mGlu5 NAM program in neurological diseases.
Aditum Bio, based in Oakland, was established by industry veterans Joe Jimenez and Mark Fishman to fund clinical development.
Sosei Heptares says it will to receive an unspecified upfront payment plus a strategic equity stake in Tempero Bio, plus future success-based milestone payments and tiered royalties.
Tempero Bio has in-licensed exclusive global rights to Sosei Heptares’ mGlu5 negative allosteric modulator (NAM) program to develop therapies targeting substance use disorders and anxiety. Tempero Bio will be funded by Aditum Bio.
It will obtain exclusive global rights to a portfolio of potent, orally available metabotropic glutamate receptor 5 (mGlu5) NAM modulators, including HTL0014242, which were precision-designed by Sosei Heptares using its GPCR Structure-Based Drug Design (SBDD) platform. The candidate HTL0014242 will be renamed TMP-301.
Tempero Bio will also gain access to a substantial clinical and preclinical data package, patents and proprietary know-how on the program generated by Sosei Heptares.
Joe Jimenez said: “The mGlu5 NAM program from Sosei Heptares fits our selection criteria very well, offering clear opportunities for the development of important new products for addiction and anxiety.
“The reported rates of both conditions have increased since the onset of the COVID-19 pandemic according to the US Center for Disease Control. We are delighted to enter this new agreement, and through Tempero Bio to advance this program through clinical trials for the benefit of patients.”
Shinichi Tamura, President and CEO of Sosei Heptares, added: “Aditum is pioneering an exciting new company and asset development model that combines their significant and proven experience in drug development with the potential to rapidly accelerate clinical trial execution through TrialSpark.
“We are delighted that, through Tempero Bio, our clinical stage mGlu5 NAM program will be one of the first programs to be advanced using this new approach.
“This exciting new agreement adds another co-owned investment to our portfolio, which we believe can be a route to creating new products for patients and long-term value for shareholders.”